Angiotensin-converting Enzyme 2 (ACE2) Proteins of Different Bat Species Confer Variable Susceptibility to SARS-CoV Entry
Overview
Affiliations
The discovery of SARS-like coronavirus in bats suggests that bats could be the natural reservoir of SARS-CoV. However, previous studies indicated the angiotensin-converting enzyme 2 (ACE2) protein, a known SARS-CoV receptor, from a horseshoe bat was unable to act as a functional receptor for SARS-CoV. Here, we extended our previous study to ACE2 molecules from seven additional bat species and tested their interactions with human SARS-CoV spike protein using both HIV-based pseudotype and live SARS-CoV infection assays. The results show that ACE2s of Myotis daubentoni and Rhinolophus sinicus support viral entry mediated by the SARS-CoV S protein, albeit with different efficiency in comparison to that of the human ACE2. Further, the alteration of several key residues either decreased or enhanced bat ACE2 receptor efficiency, as predicted from a structural modeling study of the different bat ACE2 molecules. These data suggest that M. daubentoni and R. sinicus are likely to be susceptible to SARS-CoV and may be candidates as the natural host of the SARS-CoV progenitor viruses. Furthermore, our current study also demonstrates that the genetic diversity of ACE2 among bats is greater than that observed among known SARS-CoV susceptible mammals, highlighting the possibility that there are many more uncharacterized bat species that can act as a reservoir of SARS-CoV or its progenitor viruses. This calls for continuation and expansion of field surveillance studies among different bat populations to eventually identify the true natural reservoir of SARS-CoV.
Effect of polymorphism in Rhinolophus affinis ACE2 on entry of SARS-CoV-2 related bat coronaviruses.
Li P, Hu J, Liu Y, Ou X, Mu Z, Lu X PLoS Pathog. 2023; 19(1):e1011116.
PMID: 36689489 PMC: 9904459. DOI: 10.1371/journal.ppat.1011116.
Frank H, Enard D, Boyd S Proc Biol Sci. 2022; 289(1979):20220193.
PMID: 35892217 PMC: 9326293. DOI: 10.1098/rspb.2022.0193.
Tian J, Sun J, Li D, Wang N, Wang L, Zhang C Cell Rep. 2022; 39(11):110969.
PMID: 35679864 PMC: 9148931. DOI: 10.1016/j.celrep.2022.110969.
Head R, Lumbers E, Jarrott B, Tretter F, Smith G, Pringle K Pharmacol Res Perspect. 2022; 10(1):e00922.
PMID: 35106955 PMC: 8929328. DOI: 10.1002/prp2.922.
Peptides and peptidomimetics as therapeutic agents for Covid-19.
Dahal A, Sonju J, Kousoulas K, Jois S Pept Sci (Hoboken). 2021; 114(1):e24245.
PMID: 34901700 PMC: 8646791. DOI: 10.1002/pep2.24245.